An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Aggrecan, encoded by ACAN, is a major proteoglycan component of the extracellular matrix in the growth plate and articular cartilage. Aggrecan provides the hydrated gel structure important for the load-bearing properties of joints and plays a key role in cartilage and bone morphogenesis. At least 25 pathological ACAN mutations have been identified in patients with highly variable phenotypes of syndromic or non-syndromic short stature. This review provides an overview of the current understanding of ACAN and the clinical and genetic findings concerning aggrecan-associated diseases.
Keywords:
ACAN; aggrecan; bone age; disc herniation; short stature.
The structure of ACAN and the position of mutations. The black and white…
Fig. 1.
The structure of ACAN and the position of mutations. The black and
white boxes on genomic DNA (gDNA) denote the coding regions on exons 1–18 and the
untranslated regions, respectively. The mutations identified in previous studies are
shown (NM_013227.3, NP_037359.3). G1, globular domain 1; IGD, interglobular domain;
G2, globular domain 2; KS, keratin sulfate attachment domain; CS, chondroitin sulfate
attachment domain; G3, globular domain 3. The figure is modified from that of Dateki
et al. (11).
Fig. 2.
Spinal phenotype of an ACAN …
Fig. 2.
Spinal phenotype of an ACAN mutation. The radiographic image shows vertebral spicules and…
Fig. 2.
Spinal phenotype of an ACAN mutation. The radiographic image shows
vertebral spicules and severe lumbar deformity (A), and the T2-weighted magnetic
resonance image shows multiple lumbar disc herniation (white arrows) (B) in a female
patient with a heterozygous ACAN mutation (11).
Baron J, Sävendahl L, De Luca F, Dauber A, Phillip M, Wit JM, et al. Short and tall stature: a new paradigm emerges. Nat Rev Endocrinol 2015;11: 735–46. doi: 10.1038/nrendo.2015.165
-
DOI
-
PMC
-
PubMed
Roughley PJ, Mort JS. The role of aggrecan in normal and osteoarthritic cartilage. J Exp Orthop 2014;1: 8. doi: 10.1186/s40634-014-0008-7
-
DOI
-
PMC
-
PubMed
Tompson SW, Merriman B, Funari VA, Fresquet M, Lachman RS, Rimoin DL, et al. A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan. Am J Hum Genet 2009;84: 72–9. doi: 10.1016/j.ajhg.2008.12.001
-
DOI
-
PMC
-
PubMed
Nilsson O, Guo MH, Dunbar N, Popovic J, Flynn D, Jacobsen C, et al. Short stature, accelerated bone maturation, and early growth cessation due to heterozygous aggrecan mutations. J Clin Endocrinol Metab 2014;99: E1510–8. doi: 10.1210/jc.2014-1332
-
DOI
-
PMC
-
PubMed
Quintos JB, Guo MH, Dauber A. Idiopathic short stature due to novel heterozygous mutation of the aggrecan gene. J Pediatr Endocrinol Metab 2015;28: 927–32. doi: 10.1515/jpem-2014-0450
-
DOI
-
PMC
-
PubMed